Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCentury Therapeutics Inc

Century Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.68 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
1896154
Market Cap
274.48M

Momentum Score

…

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.48
Low
1.73
High
52 Week Price Range
1.28
Low
5.51
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Century Therapeutics is a clinical-stage biotechnology company developing allogeneic, induced pluripotent stem cell (iPSC)-derived T‑ and NK‑cell therapies intended to treat hematologic and solid tumors. Long-term growth drivers include its iPSC platform that may enable scalable, off-the-shelf products, potential clinical data readouts, and manufacturing scale that could reduce costs compared with autologous approaches. Investors may find exposure to next-generation cell therapy technology attractive as it appears positioned to address supply and cost limitations of personalized treatments.

Material risks include early-stage clinical and regulatory uncertainty, high cash burn and financing needs, complex manufacturing and supply challenges, and intense competition from established cell therapy and gene-editing companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.68
Dividend Yield
-
Revenue TTM
1.37M
Revenue Per Share
0.02
Gross Profit TTM
5.20M
Debt / Equity
0.26
ROE
-58.66%
Net Debt
0.85M
ROCE
-39.04%
Diluted EPS TTM
-2.43

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2016-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2016-12-31
Income before tax -130.84M -95.78M -53.58M -244.77M -
Net income -130.93M -95.82M -54.66M -245.98M -
Selling general administrative 31.86M 19.23M 9.49M 5.77M 81.39M
Gross profit 5.20M - - - 2.48M
Reconciled depreciation 8.44M 3.75M 1.40M 0.25M -
Ebit -133.83M -94.88M -53.90M -245.98M -
Ebitda -121.30M -94.51M -47.07M -18.57M -
Depreciation and amortization 12.54M 0.38M 6.83M 227.41M -
Non operating income net other 2.99M -0.90M - - -
Operating income -133.83M -94.88M -53.90M -245.98M -
Other operating expenses 139.03M 94.88M 49.18M 20.03M -
Interest expense 1.10M 1.27M 0.38M 0.00M 0.00M
Tax provision 0.09M 0.04M - - -
Net interest income -1.40M -1.27M -0.38M 0.00M -
Non recurring 10.00M - - - -
Income tax expense 0.09M 0.04M 1.08M 1.21M -
Total revenue 5.20M 0.00M 0.00M 0.00M 470.32M
Total operating expenses 139.03M 94.88M 49.18M 20.03M -
Cost of revenue - - - - 467.84M
Total other income expense net 2.99M -0.90M 0.32M 1.21M -
Net income from continuing ops -130.93M -95.82M -53.58M -244.77M -
Net income applicable to common shares -130.93M -95.82M -53.58M -244.77M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 360.69M 486.54M 437.38M 106.78M 90.90M
Intangible assets - - - 9.39M -
Other current assets 3.59M 3.44M 5.28M 0.26M 0.12M
Total liab 175.94M 183.81M 41.14M 213.19M 182.75M
Total stockholder equity 184.75M 302.74M 396.24M -106.41M -91.86M
Other current liab 9.22M 10.23M 1.08M 0.05M 1.45M
Common stock 0.01M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -655.77M -519.10M -388.17M -292.34M -238.77M
Other liab - 111.55M 2.02M - -
Other assets 0.00M 3.24M 3.49M 2.15M 0.21M
Cash 47.32M 84.27M 56.45M 27.21M 44.06M
Total current liabilities 17.85M 29.82M 15.65M 12.11M 2.99M
Current deferred revenue 4.37M 7.15M 5.32M 3.74M -
Net debt 0.85M -34.85M -32.98M -5.66M -44.06M
Short term debt 1.51M 6.98M 1.65M 0.24M -
Short long term debt - 6.50M 1.04M - -
Short long term debt total 48.17M 49.41M 23.46M 21.55M -
Other stockholder equity 840.41M 824.29M 785.05M 185.93M 146.91M
Property plant equipment - 82.78M 57.97M 24.78M 2.49M
Total current assets 176.99M 319.72M 228.15M 78.80M 84.12M
Long term investments 89.10M 51.85M 135.91M 1.05M 4.08M
Net tangible assets - 302.74M 396.24M -106.41M -91.86M
Short term investments 125.41M 231.23M 166.43M 48.54M 37.48M
Net receivables 0.67M 0.78M 0.25M 0.91M 0.12M
Long term debt - 3.74M 8.90M 9.68M -
Inventory - - -0.25M 1.88M 2.34M
Accounts payable 2.74M 5.45M 7.60M 8.08M 1.55M
Accumulated other comprehensive income 0.11M -2.46M -0.65M -0.00M -0.00M
Common stock total equity - 0.01M 0.01M 0.00M 0.00M
Retained earnings total equity - -519.10M -388.17M - -
Non currrent assets other 0.54M 3.24M 3.49M 1.24M 0.21M
Non current assets total 183.70M 166.82M 209.22M 27.98M 6.77M
Capital lease obligations 48.17M 39.17M 14.56M 11.92M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2016-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2016-12-31
Investments 17.48M -253.37M -8.21M -41.54M -
Change to liabilities 117.16M -0.36M 2.06M 1.23M -
Total cashflows from investing activities -13.13M -298.34M -22.76M -19.83M -
Net borrowings - - 9.73M 9.73M -
Total cash from financing activities 27.16M 417.77M 47.69M 74.84M 98.09M
Change to operating activities 10.74M -0.95M 2.80M 1.03M -
Net income -130.93M -95.82M -53.58M -244.77M -
Change in cash 28.08M 30.43M -16.34M 38.84M -
Begin period cash flow 58.16M 27.73M 44.06M 31.42M -
End period cash flow 86.24M 58.16M 27.73M 70.26M 31.42M
Total cash from operating activities 14.05M -89.00M -41.27M -16.17M -
Issuance of capital stock 27.16M 381.24M 0.00M 74.84M -
Depreciation 8.44M 3.75M 1.40M 0.25M -
Change to inventory - - - - 78.33M
Sale purchase of stock 27.16M 223.92M - - -
Other cashflows from financing activities -13.13M 196.16M 47.69M -19.83M -
Change to netincome 10.67M 4.66M 5.95M 226.09M -
Capital expenditures 30.60M 44.97M 9.82M 2.46M 11.12M
Cash flows other operating 8.42M -1.54M - - -
Cash and cash equivalents changes 28.08M 30.43M - - -
Change in working capital 123.94M -2.80M 4.86M 2.26M -
Stock based compensation 10.67M 4.66M 0.88M 0.15M -
Other non cash items 1.93M 1.21M 0.44M 225.95M -
Free cash flow -16.55M -133.97M -51.09M -18.63M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IPSC
Century Therapeutics Inc		 -
-%		 1.68 - - 113.40 1.37 57.66 -1.06
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Century Therapeutics Inc

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

25 North 38th Street, Philadelphia, PA, United States, 19104

267 817 5790

https://www.centurytx.com

152

Name Title Year Born
Dr. Osvaldo Flores Ph.D. Pres, CEO & Director 1963
Dr. Adrienne Farid Ph.D. Chief Operations Officer 1962
Dr. Luis Borges Chief Scientific Officer 1962
Mr. Douglas Carr CPA VP of Fin. and Operations & Sec. NA
Dr. Gregory Russotti Ph.D. Chief Technology Officer 1967
Mr. Kenneth J. Dow J.D. Head of Legal & Compliance NA
Dr. Shane Williams Ph.D. Chief People Officer NA
Dr. Michael C. Diem Chief Bus. Officer 1971
Dr. Hyam I. Levitsky M.D. Pres of R&D 1958
Mr. Mark Wallet Head of Immunology & VP NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…